182 related articles for article (PubMed ID: 19011755)
1. Role of full-length osteoprotegerin in tumor cell biology.
Zauli G; Melloni E; Capitani S; Secchiero P
Cell Mol Life Sci; 2009 Mar; 66(5):841-51. PubMed ID: 19011755
[TBL] [Abstract][Full Text] [Related]
2. Investigating the interaction between osteoprotegerin and receptor activator of NF-kappaB or tumor necrosis factor-related apoptosis-inducing ligand: evidence for a pivotal role for osteoprotegerin in regulating two distinct pathways.
Vitovski S; Phillips JS; Sayers J; Croucher PI
J Biol Chem; 2007 Oct; 282(43):31601-9. PubMed ID: 17702740
[TBL] [Abstract][Full Text] [Related]
3. Osteoprotegerin: multiple partners for multiple functions.
Baud'huin M; Duplomb L; Teletchea S; Lamoureux F; Ruiz-Velasco C; Maillasson M; Redini F; Heymann MF; Heymann D
Cytokine Growth Factor Rev; 2013 Oct; 24(5):401-9. PubMed ID: 23827649
[TBL] [Abstract][Full Text] [Related]
4. Osteoprotegerin decreases human osteoclast apoptosis by inhibiting the TRAIL pathway.
Chamoux E; Houde N; L'Eriger K; Roux S
J Cell Physiol; 2008 Aug; 216(2):536-42. PubMed ID: 18338379
[TBL] [Abstract][Full Text] [Related]
5. Factor VIII-von Willebrand factor complex inhibits osteoclastogenesis and controls cell survival.
Baud'huin M; Duplomb L; Téletchéa S; Charrier C; Maillasson M; Fouassier M; Heymann D
J Biol Chem; 2009 Nov; 284(46):31704-13. PubMed ID: 19758994
[TBL] [Abstract][Full Text] [Related]
6. Harnessing the versatile role of OPG in bone oncology: counterbalancing RANKL and TRAIL signaling and beyond.
Deligiorgi MV; Panayiotidis MI; Griniatsos J; Trafalis DT
Clin Exp Metastasis; 2020 Feb; 37(1):13-30. PubMed ID: 31578655
[TBL] [Abstract][Full Text] [Related]
7. Osteoprotegerin and RANKL differentially regulate angiogenesis and endothelial cell function.
McGonigle JS; Giachelli CM; Scatena M
Angiogenesis; 2009; 12(1):35-46. PubMed ID: 19105036
[TBL] [Abstract][Full Text] [Related]
8. Glycosaminoglycans as potential regulators of osteoprotegerin therapeutic activity in osteosarcoma.
Lamoureux F; Picarda G; Garrigue-Antar L; Baud'huin M; Trichet V; Vidal A; Miot-Noirault E; Pitard B; Heymann D; Rédini F
Cancer Res; 2009 Jan; 69(2):526-36. PubMed ID: 19147566
[TBL] [Abstract][Full Text] [Related]
9. The Role of Osteoprotegerin and Its Ligands in Vascular Function.
Rochette L; Meloux A; Rigal E; Zeller M; Cottin Y; Vergely C
Int J Mol Sci; 2019 Feb; 20(3):. PubMed ID: 30736365
[TBL] [Abstract][Full Text] [Related]
10. Pathophysiological roles of osteoprotegerin (OPG).
Reid P; Holen I
Eur J Cell Biol; 2009 Jan; 88(1):1-17. PubMed ID: 18707795
[TBL] [Abstract][Full Text] [Related]
11. Anticancer efficacy of Apo2L/TRAIL is retained in the presence of high and biologically active concentrations of osteoprotegerin in vivo.
Zinonos I; Labrinidis A; Lee M; Liapis V; Hay S; Ponomarev V; Diamond P; Findlay DM; Zannettino AC; Evdokiou A
J Bone Miner Res; 2011 Mar; 26(3):630-43. PubMed ID: 20818644
[TBL] [Abstract][Full Text] [Related]
12. Variants of Osteoprotegerin Lacking TRAIL Binding for Therapeutic Bone Remodeling in Osteolytic Malignancies.
Higgs JT; Jarboe JS; Lee JH; Chanda D; Lee CM; Deivanayagam C; Ponnazhagan S
Mol Cancer Res; 2015 May; 13(5):819-27. PubMed ID: 25636966
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis.
Canon JR; Roudier M; Bryant R; Morony S; Stolina M; Kostenuik PJ; Dougall WC
Clin Exp Metastasis; 2008; 25(2):119-29. PubMed ID: 18064531
[TBL] [Abstract][Full Text] [Related]
14. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL.
Emery JG; McDonnell P; Burke MB; Deen KC; Lyn S; Silverman C; Dul E; Appelbaum ER; Eichman C; DiPrinzio R; Dodds RA; James IE; Rosenberg M; Lee JC; Young PR
J Biol Chem; 1998 Jun; 273(23):14363-7. PubMed ID: 9603945
[TBL] [Abstract][Full Text] [Related]
15. Osteoprotegerin (OPG) and related proteins (RANK, RANKL and TRAIL) in thyroid disease.
Sood SK; Balasubramanian S; Higham S; Fernando M; Harrison B
World J Surg; 2011 Sep; 35(9):1984-92. PubMed ID: 21748518
[TBL] [Abstract][Full Text] [Related]
16. Vascular calcification in type-2 diabetes and cardiovascular disease: Integrative roles for OPG, RANKL and TRAIL.
Harper E; Forde H; Davenport C; Rochfort KD; Smith D; Cummins PM
Vascul Pharmacol; 2016 Jul; 82():30-40. PubMed ID: 26924459
[TBL] [Abstract][Full Text] [Related]
17. Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor kappaB ligand (RANKL) in human breast tumours.
Van Poznak C; Cross SS; Saggese M; Hudis C; Panageas KS; Norton L; Coleman RE; Holen I
J Clin Pathol; 2006 Jan; 59(1):56-63. PubMed ID: 16394281
[TBL] [Abstract][Full Text] [Related]
18. Genetic deletion of muscle RANK or selective inhibition of RANKL is not as effective as full-length OPG-fc in mitigating muscular dystrophy.
Dufresne SS; Boulanger-Piette A; Bossé S; Argaw A; Hamoudi D; Marcadet L; Gamu D; Fajardo VA; Yagita H; Penninger JM; Russell Tupling A; Frenette J
Acta Neuropathol Commun; 2018 Apr; 6(1):31. PubMed ID: 29699580
[TBL] [Abstract][Full Text] [Related]
19. Osteoprotegerin (OPG) binds with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL): suppression of TRAIL-induced apoptosis in ameloblastomas.
Sandra F; Hendarmin L; Nakamura S
Oral Oncol; 2006 Apr; 42(4):415-20. PubMed ID: 16413220
[TBL] [Abstract][Full Text] [Related]
20. The tumour necrosis factor-related apoptosis-inducing ligand-osteoprotegerin system in limited systemic sclerosis: a new disease marker?
Castellino G; Corallini F; Bortoluzzi A; La Corte R; Lo Monaco A; Secchiero P; Zauli G; Trotta F
Rheumatology (Oxford); 2010 Jun; 49(6):1173-6. PubMed ID: 20299382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
